Genetic Insights Into Protective Effects of GLP-1 Receptor Agonists on Stroke and Alzheimer Disease Across Ancestries
Authors:
- Ilana Caro-ChâtelierICIlana Caro-Châtelier
- Muralidharan SargurupremrajMSMuralidharan Sargurupremraj
- Chengran YangCYChengran Yang
- Callistus AkinleyeCACallistus Akinleye
- David-Alexandre TrégouëtDTDavid-Alexandre Trégouët
- Rufus Olusola AkinyemiRARufus Olusola Akinyemi
- Daichi ShigemizuDSDaichi Shigemizu
- Motunrayo CokerMCMotunrayo Coker
- Joshua O. AkinyemiJAJoshua O. Akinyemi
- Hemant K. TiwariHemant K. Tiwari
- Daniel I. ChasmanDCDaniel I. Chasman
- Bruce OvbiageleBOBruce Ovbiagele
Open Access
- 1 October 2026
- journal article
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (5) , e200425
Abstract
Background and ObjectivesStroke and dementia are leading causes of death and disability worldwide, requiring enhanced preventive strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RA), wid...Keywords
This publication has 49 references indexed in Scilit:
- Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the USAlzheimer's & Dementia, 2024
- GLP-1 programs the neurovascular landscapeCell Metabolism, 2024
- GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling studyeClinicalMedicine, 2024
- Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trialsAmerican Journal of Preventive Cardiology, 2024
- Prioritising genetic findings for drug target identification and validationAtherosclerosis, 2024
- Global Burden of Cardiovascular Diseases and Risks, 1990-2022JACC, 2023
- Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registersAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysisDiabetologia, 2021
- The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathyBrain Research, 2016
- Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's diseaseAnnals of Neurology, 1995